The myth
The same precautions fit every peptide product.
The fact
A shared storage rule does not fit all peptide medicines. The exact product’s label and pharmacy instructions are the basis for storage questions.
Basis: Read the source record
Legal and cost information is dated September 26, 2026.
FDA refers to the federal drug agency—the Food and Drug Administration.
Sources for this section
Check the medicine’s own instructions
Some products need cold storage; others do not. The product records contrast room-temperature storage for tesamorelin (EGRIFTA SV, EGRIFTA WR) with cold storage for semaglutide (Ozempic, Wegovy). A rule to refrigerate all peptides would be wrong.
An injection can cause a reaction where it enters the skin. How often that happens differs by product. A study’s reported frequency of skin reactions describes the people taking that particular drug in the study. It does not give a frequency for every peptide or predict whether you will have a reaction.
Ask for the instructions that match the exact drug name and form. If written directions differ from a general web post, take both to the pharmacist. Ask which applies and why. A statement about a different drug cannot tell someone how to handle the drug in hand.
Sources for this section
A compounded product has a different evidence gap
FDA does not review compounded drugs before marketing for safety, quality, or effectiveness. That is the September 2026 record. It also means they lack the same FDA-reviewed pregnancy and breastfeeding information found on approved labels.
FDA has reports of measurement and calculation mistakes with compounded injectable semaglutide. Some reports involved hospital care. If instructions are unclear about the medicine’s strength or the amount to measure in a syringe, ask the pharmacist or prescriber to explain them. Do not work out the amount from an online example that changes one set of units into another.
Hormones are chemicals your body makes to carry messages. GLP-1 medicines act like a messenger that helps control appetite and blood sugar. For injectable GLP-1 drugs delivered warm or without enough cold storage, FDA says not to use them because quality may be affected. That advice applies to this delivery problem. It is not a rule for storing every peptide.
Pregnancy plans and breastfeeding deserve a product-specific discussion with the prescriber. The approved labels for semaglutide and tirzepatide do not give identical advice. A broad peptide answer misses those differences.
Know where a problem goes
MedlinePlus treats severe allergic reactions as emergencies. For severe symptoms, which can include a swollen tongue or difficulty breathing, it directs people to use the emergency number locally or call 911.
FDA lets people report a drug problem through MedWatch. The person taking the drug can send a report. This is a way to report a problem, not a way to get care for it.
FDA cautions that a reported event may have another cause. Its records cannot show how common an event is. Report totals do not predict a person’s outcome.
Before leaving a visit, ask for a contact plan for the exact drug. Who can clear up the written instructions? Who handles a suspected reaction? What details will they need? Keep the answers where they are easy to find. It helps to put the drug name, form, and date with each answer. The goal is a useful conversation with the people in charge of care.
- Which storage instructions apply to this exact product?
- Who resolves unclear directions?
- What is the route for a medicine concern?